ARTICLE | Clinical News
Transdrug doxorubicin regulatory update
May 2, 2005 7:00 AM UTC
FDA granted Orphan Drug designation to Transdrug doxorubicin to treat hepatocellular carcinoma (HCC). The nanoparticle formulation of doxorubicin, which is in a European Phase I/II trial, also has Orp...